Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Phase I ARTEMIS-001 trial of the B7-H3 ADC HS-20093 (GSK5764227) now on Cancer Cell.
In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%), but no difference by platinum sensitivity. B7-H3 IHC not predictive.”
Title: HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
Authors: Jianchun Duan, Yuping Sun, Qiming Wang, Ligang Xing, Lin Wu, Liang Han, Jianhua Chen, Baogang Liu, Ping Lu, Huaqiu Shi, Xinmin Yu, Junhong Zhang, Guoping Zhang, Yanping Hu, Ying Cheng, Hongmei Sun, Haihua Yang, Zhiye Zhang, Fangling Ning, Zhiyong He, Wenxiu Yao, Yiwei Dong, Min Zhang, Baili Song, Yuanfeng Zhou, Xiangru Mao, Qingyuan Liu, Jie Wang
Read the Full Article.
Other articles featuring Stephen V Liu on OncoDaily.